Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-((((3r,5r)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic Acid
2. Gsk2330672
1. 1345982-69-5
2. Gsk2330672
3. Gsk-2330672
4. Iinerixibat
5. Linerixibat [usan]
6. Chembl2387408
7. Linerixibat (usan)
8. 386012z45s
9. 3-[[(3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2h-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic Acid
10. Pentanedioic Acid, 3-((((3r,5r)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-
11. Unii-386012z45s
12. Pentanedioic Acid, 3-[[[(3r,5r)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl]methyl]amino]-
13. Linerixibat [inn]
14. Linerixibat [jan]
15. Linerixibat [who-dd]
16. Schembl2586025
17. Bcp17155
18. Ex-a1180
19. Vdc98269
20. Bdbm50434858
21. Mfcd28386358
22. Who 10729
23. Zinc96270862
24. Cs-5447
25. Db11729
26. Gsk 2330672
27. Ac-36158
28. As-35059
29. Hy-16643
30. D11539
31. Gsk 2330672;gsk-2330672
32. J-690137
33. Q27256749
34. 3-((((3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepin-8-yl)methyl)amino)pentanedioic Acid
35. 3-((((3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro- 1h-1.lambda.6,4-benzothiazepin-8-yl)methyl)amino)pentanedioic Acid
36. 3-({[(3r,5r)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic Acid
37. 3-[[[(3r,5r)-3-bu-3-et-2,3,4,5-tetrahydro-7-ome-1,1-dioxido-5-ph-1,4-benzothiazepin-8-yl]methyl]amino]pentanedioic Acid
38. 3-[[[(3r,5r)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl]methyl]amino]pentanedioic Acid
| Molecular Weight | 546.7 g/mol |
|---|---|
| Molecular Formula | C28H38N2O7S |
| XLogP3 | -1.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 13 |
| Exact Mass | 546.23997273 g/mol |
| Monoisotopic Mass | 546.23997273 g/mol |
| Topological Polar Surface Area | 150 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of primary biliary cholangitis
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Linerixibat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Linerixibat, including repackagers and relabelers. The FDA regulates Linerixibat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Linerixibat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Linerixibat supplier is an individual or a company that provides Linerixibat active pharmaceutical ingredient (API) or Linerixibat finished formulations upon request. The Linerixibat suppliers may include Linerixibat API manufacturers, exporters, distributors and traders.
Linerixibat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Linerixibat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Linerixibat GMP manufacturer or Linerixibat GMP API supplier for your needs.
A Linerixibat CoA (Certificate of Analysis) is a formal document that attests to Linerixibat's compliance with Linerixibat specifications and serves as a tool for batch-level quality control.
Linerixibat CoA mostly includes findings from lab analyses of a specific batch. For each Linerixibat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Linerixibat may be tested according to a variety of international standards, such as European Pharmacopoeia (Linerixibat EP), Linerixibat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Linerixibat USP).
LOOKING FOR A SUPPLIER?
